Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Oct 17, 2022

Paula Brown Stafford is the President, CEO, and Chairman of Novan, which is focused on the research, development, and commercialization of therapies for skin diseases using a novel chemical entity.  The first target indication is molluscum contagiosum, a highly contagious viral skin infection caused by molluscipoxvirus with no current FDA-approved treatment.

Paula explains, "The prevalence in the U.S. is around 6 million people, in terms of who gets it. In our clinical trials, which seem to be indicative of the normal population, the average age of the patient is about six and a half, primarily children, one year of age to 14, are the ones who get or are susceptible to this virus."

"Our product candidate is Berdazimer gel 10.3%. It's a topical gel under investigation here at Novan to be a first-in-class therapy for the treatment of molluscum. The active ingredient is Berdazimer sodium, which is a nitric oxide- releasing agent. Our other products potentially for acne, potentially for other areas like psoriasis, et cetera, may have a different percentage number after Berdazimer gel because it refers to the amount of nitric oxide that's in the final product."

@Novan_Biotech #Novan #Dermatology #Molluscum #Pediatrics

Listen to the podcast here